Navigation Links
OU researcher developing novel therapy for Alzheimer's disease
Date:7/8/2010

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patientan approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

Peter J. Heinzelman, an associate professor in the Department of Chemical, Biological and Mechanical Engineering, recently received a $75,000 grant from the Oklahoma Center for the Advancement of Science and Technology to pursue this research, which includes the development of a library of biopharmaceutical proteases for public use.

Heinzelman's previous research led to the idea that proteases, or proteins that degrade other proteins, would be more effective as a therapy for Alzheimer's disease than existing approaches. The brain is surrounded by a barrier of cells that allows glucose to pass through but is resistant to drug molecules and therapeutic proteins.

By virtue of a single protease molecule able to degrade thousands of the plaque molecules, these proteases should be capable of delivering a catalytic benefit even if only small amounts pass through the cell barrier surrounding the brain.

"Digestive enzymes are promiscuous," says Heinzelman. "We can create catalytic proteases that attack the beta-amyloid plaque that cause neurons in the brain to die. Current therapies use amyloid-binding antibodies that are created by the body or injected to get rid of the plaque, but these antibodies used to attack the problematic Abeta molecules can only bind one time and clear one Abeta molecule, then they are done."

The delivery system is problematic, too. Heinzelman suggests an approach that addresses both therapeutic efficacy and delivery. He wants to re-engineer an existing technology to link proteases with "ferrying" antibodies that can encourage passage of the proteases from the circulation side across the brain cell barrier and into the brain tissue. This approach has been demonstrated in the laboratory.

Another aspect of the OCAST grant is the development of a library of proteases that will be made freely available and could become a powerful tool for the scientific community. Heinzelman is working with researchers from the University of Wisconsin-Madison and the Oklahoma Medical Research Foundation on this grant.


'/>"/>

Contact: Jana Smith
jana.smith@ou.edu
405-325-1322
University of Oklahoma
Source:Eurekalert

Related medicine news :

1. Researchers identify factors behind blood-making stem cells
2. Parkinsons Transplant Mystery Solved, Researchers Say
3. BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
4. Researchers suggest new paradigm for breast cancer screening
5. Of lice and man: Researchers sequence human body louse genome
6. AcademyHealth honors leading health services researchers
7. UCLA researchers, US military collaborate to open center for traumatic brain injury
8. Texas A&M researcher explains how embryo fights retroviral infection
9. UC San Diego researcher awarded $5.3 million for breast cancer survivorship study
10. UCSD researchers receive $2.5 million in new stem cell grants
11. Researchers find key to getting estrogens benefits without cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: